Modality
Nanobody
MOA
AuroraAi
Target
PCSK9
Pathway
Sphingolipid
DMDBladder CaPSP
Development Pipeline
Preclinical
~Apr 2016
→ ~Jul 2017
Phase 1
Oct 2017
→ Jul 2026
Phase 1Current
NCT05234301
446 pts·Bladder Ca
2017-10→2026-07·Terminated
446 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-07-204mo awayInterim· Bladder Ca
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
P1
Termina…
Catalysts
Interim
2026-07-20 · 4mo away
Bladder Ca
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05234301 | Phase 1 | Bladder Ca | Terminated | 446 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA | |
| BMR-8377 | BioMarin | Phase 1/2 | PCSK9 |